Each year, Rare Disease Day provides an opportunity to reflect on the global impact of rare conditions and to reaffirm our collective commitment to improving outcomes for those affected. In 2026, the theme is equity – a principle that’s fundamental to progress in rare disease research and care.
Rare diseases are individually uncommon, yet collectively they affect millions of people worldwide. Many are complex, multi-system conditions that present challenges in recognition, diagnosis and treatment, resulting in prolonged journeys to answers for patients and families and uncertainty about the future.
Mitochondrial disease is one example of a rare disease. By affecting how cells produce the energy required for life, it can impact multiple organs and systems.
Like many rare diseases, mito highlights the importance of sustained research, collaboration and global awareness.
What does equity mean?
We can explain equity by thinking about the concept of ‘balancing scales’:
Equity in rare disease means improving visibility.
It means reducing diagnostic delays.
It means ensuring research progress translates into meaningful outcomes for patients and families.
Equity doesn’t happen overnight
Achieving equity comes through incremental advances: refining our understanding of disease mechanisms, identifying new genetic insights, developing improved diagnostic pathways and exploring potential therapeutic strategies. Each discovery, however small, contributes to a broader shift towards more equitable outcomes.
Equity is not simply about equal distribution; it’s about recognising differing needs and addressing gaps where they exist. In the context of rare diseases, this includes reducing diagnostic delays, broadening access to specialist expertise and ensuring that research efforts reflect the diversity of affected communities.
Moving towards an equitable future for all
On Rare Disease Day, we recognise the importance of equitable research, inclusive collaboration and continued commitment to understanding rare conditions such as mitochondrial disease.
Because advancing equity in rare disease research is how we move closer to changing lives.
